ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0475

Ferric Pyrophosphate Citrate (Triferic® AVNU) Injection: Alternate Intravenous Dosing Using a Spring-Driven External Infusion Pump

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Abdellatif, Abdul A., Clear Lake Specialties, Houston, Texas, United States
  • Pratt, Raymond D., Rockwell Medical Inc, Wixom, Michigan, United States

Ferric pyrophosphate citrate injection (FPC-IV) is an iron replacement product to maintain hemoglobin by intravenous infusion (IV) over 3 to 4 hours. Some hemodialysis (HD) centers cannot use HD system syringe pumps for drug administration. We investigated the use of a spring-driven syringe pump to infuse FPC IV into the pre-or post dialyzer blood lines.


An open-label, study was conducted in 12 HD patients at 6 treatments. FPC-IV (6.75mg Fe/4.5 mL) was drawn up into 20 mL syringes. The syringe was attached to a flow-restrictor tubing 2 mL/hr (nominal rate) and then attached to the the pre-Dialyzer blood line port or to the venous drip chamber. The syringe was placed in the chamber of the FreedomEdge® Pump (FP) and the pump activated. Blood for serum iron (sFe) and transferrin saturation (TSAT) was collected pre-hemodialysis and immediately post infusion.


FP Delivery of FPC took an average of 134 ± 31.7 minutes (Range 71 to 195 min). The mean increment in sFe pre- to post infusion was 202 ± 73.7 µg/dL. The pump set up, including loading the syringe, took an average of 109 ± 42.7 sec (Range: 48 to 251 sec.). The incremental sFe in this study is compared to the dialysate and IV FPC infusions over 3 hours in Figure 1. The sFe was rapidly cleared with no increase in pre-dialysis sFe. FPC-IV was well tolerated with no reported adverse events.


The results of this study demonstrate that FPC-IV can be safely administered as a continuous infusion using a spring-driven pump (FP) over 71 to 195 minutes. The increment in sFe is slightly greater than the 3 or 4-hour FPC infusions due to the shorter administration time. A spring-driven infusion pump to administer FPC IV is well-tolerated and a suitable alternative to use of the Hemodialysis machine syringe pump.

Figure 1. Comparison of pre- and post-dialysis sFe across FPC studies.


  • Commercial Support